What Symbio does

Symbio Generrics India Pvt Ltd is a Bengaluru-based, research-driven Active Pharmaceutical Ingredient (API) manufacturer and Contract Development and Manufacturing Organization (CDMO) founded in 2010-2011 and privately held with private equity backing from Ascent Capital since 2022. The company operates three fully integrated manufacturing facilities - the flagship Vizag plant (six acres, capacity scalable to over 600 KL, WHO-GMP certified, USFDA/EUGMP audits pending), the VPL Chemicals facility near Bangalore (ANVISA- and WHO-GMP-approved with CEPs/COPSs), and the Tumkur facility (focused on enzyme-based APIs and biocatalytic processes) - alongside a 1+ acre state-of-the-art R&D centre in Jigani, Bangalore with up to 100 fume hoods and a specialized peptide research wing. Its product portfolio spans 25+ API molecules across cardiovascular, metabolic, CNS, gastrointestinal, and enzymatic therapeutic categories, with named exposure to high-value molecules including Semaglutide, Finerenone, Vonoprazan, and Resmetirom in the development pipeline.

The company generates revenue through B2B sales of APIs, pharmaceutical intermediates, pre-formulated pellets and granules, and CDMO services to global pharmaceutical formulation companies. Pricing is not publicly disclosed; the model relies on direct enterprise sales relationships and contract negotiations rather than standardized pricing. Customers include Abbott (Samanvay Award recipient) and unnamed global pharmaceutical leaders, with exports to 40+ countries including Germany, Spain, Portugal, Brazil, Mexico, Australia, South Korea, Turkey, and Russia. The go-to-market emphasizes scientific expertise, regulatory certification (ANVISA, CEP, WHO-GMP), and long-term partnership development. Manufacturing differentiation rests on green chemistry principles, enzymatic synthesis, biocatalytic processes, and solvent recovery systems. The company employs 51-100 staff and operates with a 20-acre land bank to support future scaling.

Operationally, Symbio combines API manufacturing with a distinct CDMO services vertical covering custom synthesis, process development, scale-up, and technology transfer for complex chemistry and high-potency molecules. Regulatory positioning across multiple jurisdictions creates switching costs and entry barriers, while vertical integration from intermediates to APIs supports supply reliability. The company completed an EcoVadis ESG assessment and runs CSR programs through the Agastya Foundation and Bhagavatula Charitable Trust. Leadership comprises Founder & Chairman Salim Shaikh, MD & CEO Akash Puranik, COO Vivek Gupta, and SVP-R&D Dr. Anil Holkar, with Ascent Capital partner Deepak Gowda on the board.

Name

Symbio

Legal name

Symbio Generrics India Pvt Ltd

Website

https://symbiogenerics.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

51–100 employees

Short description

Symbio Generrics is a Bengaluru-headquartered, Ascent Capital-backed API manufacturer and CDMO operating three manufacturing facilities and an R&D centre, supplying 25+ molecules across cardiovascular, metabolic, CNS, gastrointestinal, and enzymatic categories to global pharmaceutical formulators in 40+ countries.

Ownership category

akta.pro rank

Product category

Active Pharmaceutical Ingredient (API) Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

Keywords

• Active pharmaceutical ingredients
• Pharmaceutical contract manufacturing
• CDMO services
• Pharmaceutical intermediates
• Enzyme-based APIs

Headquarters

HQ city

Bengaluru

HQ country

India

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Active Pharmaceutical Ingredients (APIs): Symbio manufactures and supplies high-quality APIs across 25+ molecules to global pharmaceutical markets. Revenue is generated through the sale of proprietary and generic APIs to pharmaceutical formulation companies worldwide, with a portfolio spanning multiple therapeutic areas including cardiovascular, metabolic, neurological, and gastrointestinal conditions.
2. Pharmaceutical Intermediates: Leveraging backward-integrated manufacturing systems, Symbio supplies premium-grade pharmaceutical intermediates that meet international quality standards. The integrated approach ensures a dependable supply chain supporting seamless progression from intermediate to finished API.
3. Contract Development and Manufacturing Organization (CDMO): Symbio offers comprehensive CDMO services including custom synthesis, process development, scale-up, and technology transfer for both regulated and emerging markets. The platform supports partners from early development through large-scale commercial production, transforming challenging chemistry into commercially viable processes.
4. Pellets and Granules: Pre-formulated bulk products including pellets and granules for pharmaceutical enzymes and select APIs, enabling partners to directly compress tablets or fill capsules. This ready-to-use format saves development time, formulation effort, and cost for pharmaceutical partners.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Symbio is a research-led pharmaceutical manufacturer that produces and globally supplies high-quality Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, enzyme-based APIs, and pre-formulated pellets and granules for pharmaceutical formulation companies. The company operates a unified CDMO platform enabling custom synthesis, process development, scale-up, and technology transfer for complex and high-potency molecules across regulated and emerging markets.

Product overview

Symbio is a research-driven pharmaceutical company specializing in manufacturing and global supply of high-quality Active Pharmaceutical Ingredients (APIs), intermediates, and pharmaceutical enzymes. The company operates a unified platform consisting of: (1) Three manufacturing facilities — Symbio Vizag (flagship advanced API and CDMO manufacturing), VPL Chemicals near Bangalore (ANVISA/WHO-GMP approved API and pellets/granules facility), and Symbio Tumakuru (enzyme-based API production); (2) A state-of-the-art R&D Centre in Bangalore driving API innovation and CDMO capabilities; (3) A CDMO services platform for custom synthesis, process development, scale-up, and technology transfer. The product portfolio spans 25+ molecules across multiple therapeutic areas including cardiovascular, metabolic, CNS, gastrointestinal, and enzymatic products, organized as Symbio Vizag APIs, VPL Chemical APIs, Tumakuru enzyme-based APIs, Pellets & Granules, CMO specialty products, India market products, and a development pipeline of Semaglutide, Tegoprazan, Ferric Carboxymaltose, and other advanced molecules.

Differentiator

Problem solved

Functional benefit

Brands

• VPL Chemicals: A Symbio Group Company - 100% Symbio-owned API and pellets manufacturing facility, ANVISA and WHO-GMP approved, located near Bangalore
• Symbio Vizag
• Symbio Tumakuru
• VPL Chemical

Products and services

• Symbio Vizag Active Pharmaceutical Ingredients High-quality Active Pharmaceutical Ingredients manufactured at Symbio's flagship Vizag facility, including Ursodeoxycholic Acid, Tauro-Ursodeoxycholic Acid, Nor-Ursodeoxycholic Acid, Edoxaban, Empagliflozin, Minoxidil, Oxcarbazepine, Verapamil, Finerenone, Vonoprazan, and Resmetirom, supplied to global pharmaceutical formulation companies.
• VPL Chemical Active Pharmaceutical Ingredients High-quality Active Pharmaceutical Ingredients manufactured at the VPL Chemicals facility near Bangalore, including Minoxidil (CEP), Eslicarbazepine, Fexofenadine, Ambroxol, and Pregabalin, supplied with Certificates of Suitability (CEPs/COPPs) for global regulatory compliance.
• Symbio Tumakuru Enzyme-Based APIs Enzyme-based Active Pharmaceutical Ingredients produced at the GMP-compliant Tumkur facility through enzymatic synthesis and biocatalysis, including Valganciclovir, Pancreatin IP/USP/Ph Eur, Trypsin Chymotrypsin, Trypsin BP, Alpha Chymotrypsin, Ox Bile, Pepsin IP, and Rutoside Trihydrate BP, supplied to pharmaceutical formulation companies.
• Pellets and Granules Pre-formulated bulk pellets and granules, including Pancreatin Pellets/Granules, Trypsin-Bromelain-Rutoside combinations, Alpha Lipoic Acid Pellets/Granules, Trypsin Chymotrypsin E.C. Granules, Orlistat Pellets, Serratiopeptidase E.C. Granules, and Dabigatran Pellets, enabling partners to directly compress tablets or fill capsules.
• CMO Specialty Products Specialty pharmaceutical contract-manufactured products including CoEnzyme Q10, Chondroitin Sulphate, Levocarnitine, Glucosamine, and L-Carnitine L-Tartrate, manufactured for pharmaceutical partners under CMO arrangements.
• India Market Products Pharmaceutical products targeted at the India market, including Montelukast, Rocuronium Bromide, Dydrogesterone, Tranexamic Acid IP, Alpha Lipoic Acid IP, Bromelain 2400GDU, Enoxaparin Sodium IP/USP, Heparin Sodium IP, Acarbose IP, Tofacitinib Citrate IP, Lactulose IP/USP/BP/Ph Eur, Sitagliptin IP, Tacrolimus IP/USP, and Mifepristone IP.
• CDMO Services Contract Development and Manufacturing Organization services supporting custom synthesis, process development, scale-up, and technology transfer for advanced intermediates, complex chemistry projects, and niche high-potency molecules for global pharmaceutical and biotech partners across regulated and emerging markets.

Quantifiable outcome

• Samanvay Award from Abbott for customer excellence
• +1 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Agastya FoundationcoreOthersSymbio's collaboration with Agastya Foundation brings hands-on science education to children in underserved communities through a Mobile Science Lab. The initiative makes science accessible, interactive, and inspiring - helping over 2,000 students across 20 government schools experience learning through experimentation. It nurtures curiosity, builds scientific temper, and sparks a lifelong passion for discovery.
• Bhagavatula Charitable Trust (BCT)coreOthersSymbio has launched skill development programs in collaboration with Bhagavatula Charitable Trust, a respected 50-year-old NGO. These programs empower women and men from underprivileged backgrounds with technical and professional skills needed to thrive within Vizag's expanding industrial ecosystem, enabling them to participate confidently and sustainably in India's manufacturing growth story.

Scale indicators8 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• Syngene International: India-headquartered contract research, development, and manufacturing organisation serving global innovator pharma. Comparable to Symbio's CDMO business in serving global pharma partners with custom synthesis and process development, though Syngene is significantly larger and more discovery-research-oriented.
• Aurobindo Pharma: Large Indian generic and API manufacturer with global filings and vertically integrated API-to-formulation operations. Relevant to Symbio as a comparator for scale of API portfolio and global export footprint, though much broader in finished dosage forms.
• Piramal Pharma Solutions: Global CDMO offering API development and manufacturing services across multiple therapeutic areas with facilities in India, North America, and Europe. Comparable to Symbio's CDMO platform in custom synthesis and complex chemistry, though at significantly larger and more diversified scale.
• Jubilant Pharmova: Indian pharma company with API, CDMO, and radiopharmaceutical businesses, including Jubilant Biosys for contract research. Comparable to Symbio's CDMO and small-molecule API operations, though broader including radiopharma and generics.

Direct peers

• MSN Laboratories: Indian API and finished dosage manufacturer with growing CDMO presence, exporting to regulated markets including US and EU. Comparable to Symbio in API manufacturing scale, regulatory compliance focus, and global export ambitions, though MSN has deeper USFDA track record.
• Laurus Labs: Indian API and CDMO manufacturer with a diversified portfolio across cardiovascular, anti-retroviral, and other therapeutic APIs, plus contract development services. Symbio shares Laurus's mid-cap, research-led, multi-facility Indian API manufacturing model, though Laurus has deeper USFDA-validated scale.
• Suven Pharmaceuticals: Indian CRAMS (Contract Research and Manufacturing Services) company specialising in small-molecule API development and manufacturing for global pharma. Closely comparable to Symbio in business model, therapeutic focus on CNS and specialty APIs, and mid-cap CDMO positioning.
• Divi's Laboratories: One of India's largest API and intermediate manufacturers with a major CDMO platform serving global pharma. Comparable to Symbio in small-molecule API manufacturing, custom synthesis, and process chemistry depth, though at materially larger scale and with established USFDA approval.
• Granules India: Indian API and pharmaceutical formulation manufacturer with significant global generics footprint. Comparable to Symbio in API portfolio breadth and pellet/granule offerings (Granules is known for pellets); both target similar regulated export markets.

Emerging players

• Sequent Scientific: Indian active pharmaceutical ingredient manufacturer with veterinary and select human health APIs. Less direct than the top peers but comparable as an India-headquartered, research-led API exporter operating in regulated and emerging markets, with overlapping supply-chain and regulatory themes.

Market position

Strengths5 records

Weaknesses3 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/symbiogenerics

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Symbio